Rifampin isoniazid pyrazinamide: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
{ | |||
__NOTOC__ | |||
| | {{Isoniazid}} | ||
{{CMG}} ; {{AE}} {{chetan}} | |||
==Overview== | |||
'''Isoniazid''', also known as '''isonicotinylhydrazine''' ('''INH'''), is an [[organic compound]] that is the first-line medication in prevention and treatment of [[tuberculosis]]. The compound was first synthesized in the early 20th century,<ref>{{Cite journal|author=Meyer H, Mally J|title=On hydrazine derivatives of pyridine carbonic acids|journal=Monatshefte Chemie verwandte Teile anderer Wissenschaften|volume=33|pages=393–414|doi = 10.1007/BF01517946|language=German|year=1912}}[http://springerlink.metapress.com/content/p7145p063227623j/fulltext.pdf PDF fulltext]</ref> but its activity against tuberculosis was first reported in the early 1950s, and three pharmaceutical companies attempted unsuccessfully to simultaneously patent the drug<ref>{{Cite journal|journal=Lancet|volume=373|issue=9670|pages=1148–1149|year=2009 | |||
|doi=10.1016/S0140-6736(09)60559-6|title=Fourth-generation fluoroquinolones in tuberculosis|author=Hans L Riede|pmid=19345815}}</ref> (the most prominent one being Roche, which launched its version, [http://www.rocheusa.com/about/history.html Rimifon], in 1952). The drug was first tested at [[Many Farms, Arizona|Many Farms]], a [[Navajo Nation|Navajo]] community, due to the Navajo reservation's dire tuberculosis problem and the fact that the population was [[Naïveté|naïve]] with respect to [[streptomycin]], the main tuberculosis treatment at the time.<ref>{{cite journal|last=Jones|first=David|title=The Health Care Experiments at Many Farms: The Navajo, Tuberculosis, and the Limits of Modern Medicine, 1952-1962|journal=Bulletin of the History of Medicine|year=2002|volume=76|issue=4|pages=749–790}}</ref> With the introduction of isoniazid, a cure for tuberculosis was first considered reasonable. | |||
==Category== | |||
Antimycobacterial | |||
==US Brand Names== | |||
Laniazid<sup>®</sup>, Nydrazid<sup>®</sup>, Rifamate<sup>®</sup>, Rifater<sup>®</sup>, Rifinah<sup>®</sup>, Rimactane/INH<sup>®</sup> | |||
==FDA Package Insert== | |||
'''[[Isoniazid description|Description]]''' | |||
'''| [[Isoniazid clinical pharmacology|Clinical Pharmacology]]''' | |||
'''| [[Isoniazid microbiology|Microbiology]]''' | |||
'''| [[Isoniazid indications and usage|Indications and Usage]]''' | |||
'''| [[Isoniazid contraindications|Contraindications]]''' | |||
'''| [[Isoniazid warnings and precautions|Warnings and Precautions]]''' | |||
'''| [[Isoniazid adverse reactions|Adverse Reactions]]''' | |||
'''| [[Isoniazid overdosage|Overdosage]]''' | |||
'''| [[Isoniazid clinical studies|Clinical Studies]]''' | |||
'''| [[Isoniazid dosage and administration|Dosage and Administration]]''' | |||
| | '''| [[Isoniazid compatibility reconstitution and stability|Compatibility, Reconstitution, and Stability]]''' | ||
'''| [[Isoniazid directions for use|Directions For Use]]''' | |||
'''| [[Isoniazid how supplied|How Supplied]]''' | |||
'''| [[Isoniazid labels and packages|Labels and Packages]]''' | |||
|} | ==Mechanisms of Action== | ||
==References== | |||
{{Reflist|2}} | |||
[[Category:Antibiotics]] | |||
[[Category:Wikinfect]] | |||
Revision as of 01:59, 30 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Overview
Isoniazid, also known as isonicotinylhydrazine (INH), is an organic compound that is the first-line medication in prevention and treatment of tuberculosis. The compound was first synthesized in the early 20th century,[1] but its activity against tuberculosis was first reported in the early 1950s, and three pharmaceutical companies attempted unsuccessfully to simultaneously patent the drug[2] (the most prominent one being Roche, which launched its version, Rimifon, in 1952). The drug was first tested at Many Farms, a Navajo community, due to the Navajo reservation's dire tuberculosis problem and the fact that the population was naïve with respect to streptomycin, the main tuberculosis treatment at the time.[3] With the introduction of isoniazid, a cure for tuberculosis was first considered reasonable.
Category
Antimycobacterial
US Brand Names
Laniazid®, Nydrazid®, Rifamate®, Rifater®, Rifinah®, Rimactane/INH®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | Compatibility, Reconstitution, and Stability | Directions For Use | How Supplied | Labels and Packages
Mechanisms of Action
References
- ↑ Meyer H, Mally J (1912). "On hydrazine derivatives of pyridine carbonic acids". Monatshefte Chemie verwandte Teile anderer Wissenschaften (in German). 33: 393&ndash, 414. doi:10.1007/BF01517946.PDF fulltext
- ↑ Hans L Riede (2009). "Fourth-generation fluoroquinolones in tuberculosis". Lancet. 373 (9670): 1148&ndash, 1149. doi:10.1016/S0140-6736(09)60559-6. PMID 19345815.
- ↑ Jones, David (2002). "The Health Care Experiments at Many Farms: The Navajo, Tuberculosis, and the Limits of Modern Medicine, 1952-1962". Bulletin of the History of Medicine. 76 (4): 749–790.